Literature DB >> 25359357

An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome.

Keith C Meyer1, Ganesh Raghu2, Geert M Verleden3, Paul A Corris4, Paul Aurora5, Kevin C Wilson6, Jan Brozek7, Allan R Glanville8.   

Abstract

Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is associated with poor survival. The International Society for Heart and Lung Transplantation, American Thoracic Society, and European Respiratory Society convened a committee of international experts to describe and/or provide recommendations for 1) the definition of BOS, 2) the risk factors for developing BOS, 3) the diagnosis of BOS, and 4) the management and prevention of BOS. A pragmatic evidence synthesis was performed to identify all unique citations related to BOS published from 1980 through to March, 2013. The expert committee discussed the available research evidence upon which the updated definition of BOS, identified risk factors and recommendations are based. The committee followed the GRADE (Grading of Recommendation, Assessment, Development and Evaluation) approach to develop specific clinical recommendations. The term BOS should be used to describe a delayed allograft dysfunction with persistent decline in forced expiratory volume in 1 s that is not caused by other known and potentially reversible causes of post-transplant loss of lung function. The committee formulated specific recommendations about the use of systemic corticosteroids, cyclosporine, tacrolimus, azithromycin and about re-transplantation in patients with suspected and confirmed BOS. The diagnosis of BOS requires the careful exclusion of other post-transplant complications that can cause delayed lung allograft dysfunction, and several risk factors have been identified that have a significant association with the onset of BOS. Currently available therapies have not been proven to result in significant benefit in the prevention or treatment of BOS. Adequately designed and executed randomised controlled trials that properly measure and report all patient-important outcomes are needed to identify optimal therapies for established BOS and effective strategies for its prevention. ©ERS 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25359357     DOI: 10.1183/09031936.00107514

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  116 in total

1.  ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine.

Authors:  Gaëtane C Michaud; Colleen L Channick; Chad R Marion; Robert M Tighe; James A Town; Andrew M Luks; Jeremy B Richards; Sucharita Kher; Prerna Mota; Gina Hong; Natalie E West; Craig Rackley; Luke Neilans; Josanna Rodriguez-Lopez; Hilary DuBrock; Cassie C Kennedy; Diana J Kelm; Carey C Thomson
Journal:  Ann Am Thorac Soc       Date:  2015-09

2.  Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.

Authors:  Hrishikesh S Kulkarni; Wida S Cherikh; Daniel C Chambers; Victoria C Garcia; Ramsey R Hachem; Daniel Kreisel; Varun Puri; Benjamin D Kozower; Derek E Byers; Chad A Witt; Jennifer Alexander-Brett; Patrick R Aguilar; Laneshia K Tague; Yuka Furuya; G Alec Patterson; Elbert P Trulock; Roger D Yusen
Journal:  J Heart Lung Transplant       Date:  2018-09-25       Impact factor: 10.247

3.  Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival.

Authors:  Chad A Newton; Julia Kozlitina; Jefferson R Lines; Vaidehi Kaza; Fernando Torres; Christine Kim Garcia
Journal:  J Heart Lung Transplant       Date:  2017-02-04       Impact factor: 10.247

4.  Dectin-1 genetic deficiency predicts chronic lung allograft dysfunction and death.

Authors:  Daniel R Calabrese; Ping Wang; Tiffany Chong; Jonathan Hoover; Jonathan P Singer; Dara Torgerson; Steven R Hays; Jeffrey A Golden; Jasleen Kukreja; Daniel Dugger; Jason D Christie; John R Greenland
Journal:  JCI Insight       Date:  2019-11-14

5.  Azithromycin Fails to Prevent Accelerated Airway Obliteration in T-bet-/- Mouse Lung Allograft Recipients.

Authors:  E A Lendermon; J M Dodd-O; T A Coon; X Wang; C R Ensor; N Cardenes; C L Koodray; H L Heusey; M F Bennewitz; P Sundd; G C Bullock; I Popescu; L Guo; C P O'Donnell; M Rojas; J F McDyer
Journal:  Transplant Proc       Date:  2018-03-09       Impact factor: 1.066

6.  Zbtb7a induction in alveolar macrophages is implicated in anti-HLA-mediated lung allograft rejection.

Authors:  Deepak K Nayak; Fangyu Zhou; Min Xu; Jing Huang; Moriya Tsuji; Jinsheng Yu; Ramsey Hachem; Andrew E Gelman; Ross M Bremner; Michael A Smith; Thalachallour Mohanakumar
Journal:  Sci Transl Med       Date:  2017-07-12       Impact factor: 17.956

Review 7.  [Fibrotic remodeling of the lung following lung and stem-cell transplantation].

Authors:  Christopher Werlein; Max Ackermann; Thia Leandra Hoffmann; Florian Laenger; Danny Jonigk
Journal:  Pathologe       Date:  2021-01-08       Impact factor: 1.011

8.  Spirometry States the Obvious: Recognizing Bronchiolitis Obliterans Syndrome Early after Hematopoietic Cell Transplantation.

Authors:  Elizabeth A Belloli; Vibha N Lama
Journal:  Ann Am Thorac Soc       Date:  2016-11

Review 9.  Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome After Lung Transplantation.

Authors:  Ramsey Hachem; Paul Corris
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

Review 10.  Azithromycin for the Treatment of Obliterative Bronchiolitis after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Hemang Yadav; Steve G Peters; Karina A Keogh; William J Hogan; Patricia J Erwin; Colin P West; Cassie C Kennedy
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-26       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.